Nine leading global pharmaceutical companies announced broad agreements with the Trump administration on Friday to lower the cost of medicines for American patients in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price). This includes participating in a direct purchasing platform, TrumpRx.gov, that will allow American patients to purchase medicines at a significant discount.

The nine manufacturers include:

• Amgen
• Bristol Myers Squibb
• Boehringer Ingelheim
• Genentech
• Gilead Sciences
• GSK
• Merck
• Novartis
• Sanofi

The agreements aim to reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and certain cancers, among others.

Furthermore, the pharmaceutical manufacturers involved are committing to invest at least $150 billion collectively in U.S. manufacturing in the near term. Also, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency.

The Trump administration plans to offer tariff exemptions to the drugmakers for three years in exchange for the MFN pricing commitments.

Other Agreements

Trump previously announced agreements with AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk and Pfizer. AbbVie, Johnson & Johnson and Regeneron were not part of the announcement, but the president said that deals involving the remaining three could be announced at another time.

TrumpRx is expected to launch in early 2026.